Summit Therapeutics

Clinical trials sponsored by Summit Therapeutics, explained in plain language.

Summit Therapeutics SMMT NASDAQ

A biopharmaceutical company developing novel therapies for infectious diseases and cancer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 4 Not yet finished but already full! 1

New hope for lung cancer patients whose first treatment stopped working

Disease control Ongoing

This study tests whether adding the experimental drug AK112 to standard chemotherapy can help people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer with an EGFR mutation) whose cancer has worsened after initial targeted therapy. About 420 pa…

Phase 3 • Sponsor: Summit Therapeutics • Aim: Disease control

Last updated Jul 30, 2026 00:00 UTC

Summit Therapeutics

New hope for lung cancer patients whose first treatment stopped working